JP2019529559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529559A5 JP2019529559A5 JP2019537043A JP2019537043A JP2019529559A5 JP 2019529559 A5 JP2019529559 A5 JP 2019529559A5 JP 2019537043 A JP2019537043 A JP 2019537043A JP 2019537043 A JP2019537043 A JP 2019537043A JP 2019529559 A5 JP2019529559 A5 JP 2019529559A5
- Authority
- JP
- Japan
- Prior art keywords
- oxaloacetate
- optionally
- composition
- drug
- unit dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims 32
- 239000003814 drug Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 16
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 9
- ATOTUUBRFJHZQG-UHFFFAOYSA-N 2-amino-2-methylpropan-1-ol;8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(C)(N)CO.O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 ATOTUUBRFJHZQG-UHFFFAOYSA-N 0.000 claims 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 8
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 8
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 8
- 229940124447 delivery agent Drugs 0.000 claims 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 8
- 229960002009 naproxen Drugs 0.000 claims 8
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 8
- 229960003357 pamabrom Drugs 0.000 claims 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 7
- 229960001680 ibuprofen Drugs 0.000 claims 7
- 229960005489 paracetamol Drugs 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 230000000202 analgesic effect Effects 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 229940035676 analgesics Drugs 0.000 claims 4
- 239000000730 antalgic agent Substances 0.000 claims 4
- 230000002051 biphasic effect Effects 0.000 claims 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- -1 coatings Substances 0.000 claims 4
- 239000008393 encapsulating agent Substances 0.000 claims 4
- 239000007937 lozenge Substances 0.000 claims 4
- 239000000829 suppository Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 230000002934 lysing effect Effects 0.000 claims 3
- 150000004727 oxaloacetic acid derivatives Chemical class 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010022998 Irritability Diseases 0.000 claims 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 206010042458 Suicidal ideation Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000005032 impulse control Effects 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 210000000936 intestine Anatomy 0.000 claims 2
- 239000011976 maleic acid Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960000582 mepyramine Drugs 0.000 claims 2
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010013496 Disturbance in attention Diseases 0.000 claims 1
- 206010027951 Mood swings Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 229940086239 acetaminophen 500 mg Drugs 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229940098416 ibuprofen 400 mg Drugs 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398319P | 2016-09-22 | 2016-09-22 | |
| US62/398,319 | 2016-09-22 | ||
| PCT/US2017/052718 WO2018057737A1 (en) | 2016-09-22 | 2017-09-21 | Method to alleviate the symptoms of pms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529559A JP2019529559A (ja) | 2019-10-17 |
| JP2019529559A5 true JP2019529559A5 (OSRAM) | 2020-11-12 |
| JP7291079B2 JP7291079B2 (ja) | 2023-06-14 |
Family
ID=59997500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537043A Active JP7291079B2 (ja) | 2016-09-22 | 2017-09-21 | Ｐｍｓの症状を軽減する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11071722B2 (OSRAM) |
| EP (1) | EP3515428B1 (OSRAM) |
| JP (1) | JP7291079B2 (OSRAM) |
| KR (1) | KR102542842B1 (OSRAM) |
| AU (2) | AU2017330348B2 (OSRAM) |
| CA (1) | CA3037235A1 (OSRAM) |
| ES (1) | ES2950096T3 (OSRAM) |
| WO (1) | WO2018057737A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7291079B2 (ja) | 2016-09-22 | 2023-06-14 | アラン ビー． キャッシュ， | Ｐｍｓの症状を軽減する方法 |
| PH12022551124A1 (en) | 2020-01-01 | 2023-08-23 | Celagenex Res India Pvt Ltd | Synergistic nutritional compositions for enhancing atp efficiency |
| US20240075000A1 (en) * | 2021-01-14 | 2024-03-07 | Alan B. Cash | Treatment of pathological fatigue with oxaloacetate |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
| US4573996A (en) | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
| US4597961A (en) | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
| US4670248A (en) * | 1985-08-15 | 1987-06-02 | International Minerals & Chemical Corp. | Olivine bolus |
| US5155105A (en) | 1986-09-15 | 1992-10-13 | Bristol-Myers Squibb Company | Pharmaceutical methods for relief of dysmenorrhea and/or premenstrual syndrome and process |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| US4839174A (en) | 1987-10-05 | 1989-06-13 | Pharmetrix Corporation | Novel transdermal nicotine patch |
| US4943435A (en) | 1987-10-05 | 1990-07-24 | Pharmetrix Corporation | Prolonged activity nicotine patch |
| AT393221B (de) | 1988-02-03 | 1991-09-10 | Leopold Pharma Gmbh | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken |
| SE462463B (sv) | 1988-12-02 | 1990-07-02 | Decken Alexandra V D | Livs- och fodermedel innehaallande ketosyror |
| US4908213A (en) | 1989-02-21 | 1990-03-13 | Schering Corporation | Transdermal delivery of nicotine |
| CA2075517C (en) | 1992-04-01 | 1997-03-11 | John Wick | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5474527A (en) | 1993-03-29 | 1995-12-12 | Bettinger; David S. | Positive displacement transdermal system |
| AU6635994A (en) | 1993-04-16 | 1994-11-08 | Tufts University School Of Medicine | Method for treatment of menopausal and premenstrual symptoms |
| FR2717389B1 (fr) | 1994-03-18 | 1996-06-07 | Lvmh Rech | Utilisation du ginsénoside Ro ou d'un extrait végétal en contenant pour stimuler la synthèse du collagène. |
| US6057439A (en) | 1994-08-04 | 2000-05-02 | Pherin Corporation | Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety |
| US5612061A (en) | 1994-10-14 | 1997-03-18 | Rabkin; Simon W. | Composition and method for the treatment of premenstrual syndrome |
| JP2874583B2 (ja) | 1995-02-10 | 1999-03-24 | 日本電気株式会社 | 半導体装置の入力保護回路 |
| US5569459A (en) | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
| FR2730635B1 (fr) | 1995-02-17 | 1997-05-09 | Lvmh Rech | Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant un extrait de bertholletia |
| US5707630A (en) | 1996-01-04 | 1998-01-13 | Sabina International, Ltd. | Herbal compound for relief of PMS through menopausal symptoms |
| WO1997038701A1 (en) * | 1996-04-12 | 1997-10-23 | Neotech Medical Innovations In | Composition and method for the treatment of premenstrual syndrome |
| US5654011A (en) | 1996-07-30 | 1997-08-05 | Energetics, Inc. | Dietary supplements |
| US6987101B1 (en) | 1996-12-20 | 2006-01-17 | Schering Aktiengesellschaft | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
| EP1019034A2 (en) | 1997-07-01 | 2000-07-19 | Atherogenics, Inc. | Antioxidant enhancement of therapy for hyperproliferative conditions |
| US6537969B1 (en) * | 1997-10-24 | 2003-03-25 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
| JP2001503447A (ja) | 1998-04-27 | 2001-03-13 | カラー アクセス，インコーポレイティド | 老化皮膚の処置用組成物および方法 |
| US6905707B2 (en) | 1998-05-28 | 2005-06-14 | Medical Research Institute | Controlled release arginine alpha ketoglutarate |
| GB9820631D0 (en) | 1998-09-22 | 1998-11-18 | Unilever Plc | Hair treatment composition, method and use |
| US7692067B2 (en) | 2002-09-18 | 2010-04-06 | Mendel Biotechnology, Inc. | Yield and stress tolerance in transgenic plants |
| US6322823B1 (en) | 1999-05-27 | 2001-11-27 | Lenore C. Mannella | PMS defense: an aromatherapy compound for the relief of symptoms of premenstrual syndrome |
| US6174542B1 (en) | 1999-07-01 | 2001-01-16 | Pms Mood Food, Inc. | Dietary supplements and food products for treating symptoms of PMS |
| EP1274425A1 (en) | 2000-04-18 | 2003-01-15 | Pharmacia Corporation | Rapid-onset formulation of a selective cyclooxigenase-2 inhibitor |
| US20020006910A1 (en) | 2000-05-18 | 2002-01-17 | Dmitri Miasnikov | Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means |
| US7473426B2 (en) | 2001-02-27 | 2009-01-06 | Yun Seok Choe | Method for selectively inhibiting reuptake of serotonin and norepinephrine using yeast extract |
| US9783819B2 (en) | 2001-03-27 | 2017-10-10 | Mendel Biotechnology, Inc. | Plant tolerance to low water, low nitrogen and cold II |
| NZ533242A (en) | 2001-12-05 | 2007-11-30 | Duramed Pharmaceuticals Inc | Oral extended regime contraceptive package |
| US20030119913A1 (en) | 2001-12-20 | 2003-06-26 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
| US7897147B2 (en) | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
| DK1824470T3 (da) | 2004-12-17 | 2014-08-18 | Cash Alan Brian | Fremgangsmåde til forlængelse af levetiden og forsinke starttidspunktet for alders-relateret sygdom |
| WO2006105019A1 (en) | 2005-03-25 | 2006-10-05 | Wisconsin Alumni Research Foundation | Compounds and methods for treating seizure disorders |
| US8124598B2 (en) | 2006-09-14 | 2012-02-28 | Sharon Sageman | 7-keto DHEA for psychiatric use |
| US8399432B2 (en) | 2009-10-27 | 2013-03-19 | Lipogen Ltd. | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
| CA2784830C (en) | 2009-12-18 | 2018-03-27 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| ES2370790B2 (es) | 2010-05-25 | 2012-10-18 | Universidade De Santiago De Compostela | Uso de oxalacetato en el tratamiento de isquemia. |
| WO2011163319A2 (en) * | 2010-06-22 | 2011-12-29 | Cash Alan B | Activation of amp-protein activated kinase by oxaloacetate compounds |
| US20150210964A1 (en) | 2014-01-24 | 2015-07-30 | The Procter & Gamble Company | Consumer Product Compositions |
| US11426374B2 (en) * | 2015-02-12 | 2022-08-30 | Terra Biological LLC | Modification of the pH and other physical properties of oxaloacetic acid to allow for enhanced stability and multiple delivery systems |
| UY40582A (es) | 2016-08-17 | 2024-01-15 | Monsanto Technology Llc | MÉTODOS, COMPOSICIONES y PLANTAS MEDIANTE LA MANIPULACIÓN DEL METABOLISMO DE GIBERELINA PARA AUMENTAR EL RENDIMIENTO COSECHABLE |
| JP7291079B2 (ja) | 2016-09-22 | 2023-06-14 | アラン ビー． キャッシュ， | Ｐｍｓの症状を軽減する方法 |
| WO2018097733A2 (en) | 2016-11-23 | 2018-05-31 | Bohne Askøy As | Prevention and/or treatment of chronic fatigue syndrome |
| WO2019012159A1 (en) | 2017-07-14 | 2019-01-17 | Protea Biopharma N.V. | METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE |
| US11332432B2 (en) | 2018-09-30 | 2022-05-17 | University Of Kansas | Bioenergetically active esters for health and disease |
| US20240075000A1 (en) | 2021-01-14 | 2024-03-07 | Alan B. Cash | Treatment of pathological fatigue with oxaloacetate |
-
2017
- 2017-09-21 JP JP2019537043A patent/JP7291079B2/ja active Active
- 2017-09-21 CA CA3037235A patent/CA3037235A1/en active Pending
- 2017-09-21 ES ES17777759T patent/ES2950096T3/es active Active
- 2017-09-21 KR KR1020197011465A patent/KR102542842B1/ko active Active
- 2017-09-21 US US16/335,652 patent/US11071722B2/en active Active
- 2017-09-21 AU AU2017330348A patent/AU2017330348B2/en active Active
- 2017-09-21 EP EP17777759.6A patent/EP3515428B1/en active Active
- 2017-09-21 WO PCT/US2017/052718 patent/WO2018057737A1/en not_active Ceased
-
2021
- 2021-06-22 US US17/354,866 patent/US11865092B2/en active Active
-
2023
- 2023-11-29 US US18/523,772 patent/US12324794B2/en active Active
- 2023-12-04 AU AU2023274237A patent/AU2023274237B2/en active Active
-
2025
- 2025-05-09 US US19/204,388 patent/US20250262177A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290026A1 (ru) | Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) | |
| EP4424328A3 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| RU2017120184A (ru) | Лекарства для замедления течения болезни паркинсона | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| AR075423A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos | |
| MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
| MX336187B (es) | Metodo para tratar el mal de parkinson. | |
| Bertoldo et al. | Targeting bone metastatic cancer: Role of the mTOR pathway | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| JP2009501801A5 (OSRAM) | ||
| JP2013541583A5 (OSRAM) | ||
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| JP2019529559A5 (OSRAM) | ||
| BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
| MX395613B (es) | COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER. | |
| NZ591496A (en) | A medicinal comprising ibuprofen and paracetamol and treatment for arthritis | |
| JP2013525422A5 (OSRAM) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP2019529569A5 (OSRAM) | ||
| JP2011508727A5 (OSRAM) | ||
| RU2019102890A (ru) | Фармацевтические композиции, содержащие флурбипрофен | |
| MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. | |
| JP2016521760A5 (OSRAM) |